Pelthos Therapeutics (NYSEAMERICAN:PTHS) Stock Rating Upgraded by Zacks Research

Pelthos Therapeutics (NYSEAMERICAN:PTHS) was upgraded by Zacks Research from a “strong sell” rating to a “hold” rating in a note issued to investors on Tuesday,Zacks.com reports.

Several other analysts have also weighed in on PTHS. Oppenheimer upped their price objective on Pelthos Therapeutics from $60.00 to $62.00 and gave the company an “outperform” rating in a report on Friday, March 20th. HC Wainwright reaffirmed a “buy” rating and issued a $60.00 price objective on shares of Pelthos Therapeutics in a research note on Thursday, March 19th. Piper Sandler started coverage on shares of Pelthos Therapeutics in a research report on Friday, February 27th. They set an “overweight” rating and a $48.00 price objective on the stock. Finally, Roth Mkm dropped their target price on Pelthos Therapeutics from $57.00 to $55.00 and set a “buy” rating on the stock in a research report on Thursday, February 26th. Four research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $56.25.

Pelthos Therapeutics Stock Up 0.4%

PTHS stock opened at $22.09 on Tuesday. The business has a 50-day moving average of $23.21. The firm has a market capitalization of $74.22 million, a P/E ratio of -1.06 and a beta of 3.87. The company has a quick ratio of 1.15, a current ratio of 2.05 and a debt-to-equity ratio of 0.81. Pelthos Therapeutics has a fifty-two week low of $9.00 and a fifty-two week high of $54.29.

Hedge Funds Weigh In On Pelthos Therapeutics

A number of large investors have recently modified their holdings of the stock. Persistent Asset Partners Ltd lifted its holdings in Pelthos Therapeutics by 150.0% during the 4th quarter. Persistent Asset Partners Ltd now owns 6,007 shares of the company’s stock worth $186,000 after buying an additional 3,604 shares in the last quarter. Millennium Management LLC bought a new position in Pelthos Therapeutics during the fourth quarter worth about $343,000. Geode Capital Management LLC grew its holdings in Pelthos Therapeutics by 31.9% during the fourth quarter. Geode Capital Management LLC now owns 13,625 shares of the company’s stock valued at $422,000 after purchasing an additional 3,295 shares during the period. Knott David M Jr grew its holdings in shares of Pelthos Therapeutics by 215.5% in the 4th quarter. Knott David M Jr now owns 19,281 shares of the company’s stock valued at $598,000 after buying an additional 13,169 shares during the period. Finally, Diadema Partners LP increased its holdings in shares of Pelthos Therapeutics by 138.1% in the fourth quarter. Diadema Partners LP now owns 25,000 shares of the company’s stock worth $775,000 after acquiring an additional 14,502 shares in the last quarter. 77.96% of the stock is currently owned by institutional investors and hedge funds.

Pelthos Therapeutics Company Profile

We are a clinical-stage biotech company focused on developing and commercializing new therapeutics to alleviate pain. Our clinical focus is to selectively target the sodium ion-channel known as “NaV1.7”, as well as other receptors in the NaV family. NaV1.7 has been genetically validated as a pain receptor in human physiology. Genetic studies have shown that families with a certain inherited NaV1.7 modulation consistently show a pathology of not feeling pain. A NaV1.7 blocker is a chemical entity that modulates the structure of the sodium-channel in a way to prevent the transmission of pain perception to the central nervous system (“CNS”).